Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 5Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma, Follicular 1Glioblastoma 1Astrocytoma 1

Interventions

Specimen Handling 26Biopsy 17Magnetic Resonance Spectroscopy 16Cyclophosphamide 6Taxes 4Cetuximab 4Bevacizumab 4decitabine and cedazuridine drug combination 3Vincristine 3Prednisone 3Nivolumab 3Doxorubicin 3Azacitidine 3venetoclax 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2deltacortene 2X-Rays 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Practice Guidelines as Topic 2Platinum 2Paclitaxel 2Ipilimumab 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 30 days × Clear all
NCT06860594 2026-06-05

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡